Drugs / DM919
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06328673 | Apr 2024 → Mar 2026 overdue | neoplasm | D2M Biotherapeutics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DM-919 | “Participants will be asked to attend clinic and be given a intravenous infusion of DM919 or DM-919 in combination with pembrolizumab.” NCT06328673 ↗ |
| Action | Inhibit | “Anti-MICA/MICB monoclonal antibody” NCT06328673 ↗ |
| Modality | Monoclonal antibody | “Anti-MICA/MICB monoclonal antibody” NCT06328673 ↗ |
| Route | Intravenous | “given a intravenous infusion of DM919 or DM-919 in combination with pembrolizumab” NCT06328673 ↗ |
| Target | MICA | “Anti-MICA/MICB monoclonal antibody” NCT06328673 ↗ |
| Target | MICB | “Anti-MICA/MICB monoclonal antibody” NCT06328673 ↗ |